| Literature DB >> 28110846 |
Vincenzo Landolfo1, Carmine Fernando Gervasio2, Giuseppe Riva3, Massimiliano Garzaro1, Rita Audisio1, Giancarlo Pecorari1, Roberto Albera2.
Abstract
INTRODUCTION: Cordectomy by laringofissure and transoral laser surgery has been proposed for the treatment of early glottic cancer.Entities:
Keywords: Câncer glótico inicial; Disease free survival; Early glottic cancer; Estado de margem; Laryngeal neoplasms; Margin status; Neoplasias laríngeas; Overall survival; Sobrevida global; Sobrevida livre de doença
Year: 2016 PMID: 28110846 PMCID: PMC9442834 DOI: 10.1016/j.bjorl.2016.11.006
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Patients and tumor characteristics.
| Characteristics | N° of patients (%) | ||
|---|---|---|---|
| Group A (86 pts) | Group B (76 pts) | Total (162 pts) | |
| Male | 83 (97) | 74 (97) | 157 (97) |
| Female | 3 (3) | 2 (3) | 5 (3) |
| Current smokers | 57 (66) | 60 (79) | 117 (72) |
| Former smokers | 24 (28) | 13 (17) | 37 (23) |
| Not smoker | 5 (6) | 3 (4) | 8 (5) |
| Yes | 58 (67) | 46 (60) | 104 (64) |
| No | 28 (33) | 30 (40) | 58 (36) |
| Squamous cell carcinoma | 86 (100) | 76 (100) | 162 (100) |
| Tis | 15 (18) | 13 (17) | 28 (17) |
| T1a | 50 (58) | 47 (62) | 97 (60) |
| T1b | 21 (24) | 16 (21) | 37 (23) |
| Radiotherapy | 8 (9) | 6 (8) | 14 (9) |
| Group A | 68.54 ± 10.81 years, range 45–81 years | ||
| Group B | 65.68 ± 11.45 years, range 41–76 years | ||
| Total | 67.24 ± 10.96 years, range 41–81 years | ||
Local recurrence rate according to margin status.
| Margin status | Group A | Group B | |||
|---|---|---|---|---|---|
| N° pts | Local recurrence rate | N° pts | Local recurrence rate | ||
| Negative | 60 | 5 (8.33%) | 64 | 5 (7.81%) | 0.80 |
| Close | 12 | 1 (8.33%) | 2 | 0 (0.0%) | 0.07 |
| Positive | 14 | 3 (21.42%) | 10 | 2 (20.00%) | 0.21 |
| Entire sample | 86 | 9 (10.20%) | 76 | 7 (9.21%) | 0.10 |
Overall survival (OS) and disease free survival (DFS) according to CT stage.
| Follow-up | Group A | Group B | ||||||
|---|---|---|---|---|---|---|---|---|
| OS | DFS | OS | DFS | |||||
| 2 years | 5 years | 2 years | 5 years | 2 years | 5 years | 2 years | 5 years | |
| Entire sample | 84 (97.67%) | 57 (90.48%) | 83 (96.51%) | 54 (85.71%) | 73 (96.05%) | 52 (88.14%) | 73 (96.05%) | 51 (86.44%) |
| Tis-T1a | 64 (98.46%) | 43 (91.49%) | 63 (96.92%) | 42 (89.36%) | 59 (98.33%) | 42 (89.36%) | 59 (98.33%) | 42 (89.36%) |
| T1b | 20 (95.24%) | 14 (87.50%) | 20 (95.24%) | 12 (75.00%) | 14 (87.50%) | 10 (83.33%) | 14 (87.50%) | 9 (75.00%) |
OS, overall survival; DFS, disease free survival.
Figure 1Overall survival (OS) and disease free survival (DFS) Kaplan–Meyer curves according to CT stage.
Functional outcomes according to treatment.
| Functional outcomes | Group A | Group B | |
|---|---|---|---|
| Tracheostomy (%) | 2.33 | 7.89 | 0.04 |
| Swallowing function recovery (days) | 1.76 ± 1.23 | 5.51 ± 2.04 | 0.02 |
| Hospital stay (days) | 3.19 ± 1.85 | 6.34 ± 2.12 | 0.04 |